Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740073 | 0.82 | PDE5A (0.37) | PDE5AMEN1KMT2AKDM4ETSHR | |
| SCHEMBL7995094 | 0.71 | ALDH1A1 (0.36) | MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL5059550 | 0.70 | OPRM1 (0.52) | KDM4EOPRM1OPRK1ALDH1A1 | |
| SCHEMBL6831393 | 0.70 | HTR2A (0.36) | KDM4EOPRM1OPRK1ALDH1A1 | |
| SCHEMBL28209006 | 0.69 | PDE5A (0.41) | PDE5AMEN1KMT2AKDM4ETSHR | |
| SCHEMBL28296124 | 0.68 | GAA (0.35) | MEN1KMT2ATSHROPRM1OPRK1 | |
| SCHEMBL24177405 | 0.67 | MEN1 (0.45) | PDE5AMEN1KMT2AKDM4ETSHR | |
| SCHEMBL4881527 | 0.67 | PTPRA (0.36) | MEN1KMT2AKDM4ETSHRHTT | |
| SCHEMBL3249767 | 0.67 | CYP2D6 (0.41) | MEN1KMT2AKDM4ETSHROPRM1 | |
| SCHEMBL29365938 | 0.67 | MEN1 (0.45) | PDE5AMEN1KMT2AKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | PDE5A 2539/4885MEN1 3711/4885KMT2A 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.